We are developing dendritic cell - based vaccines
targeting telomerase, a protein expressed in over 95 percent of cancers and rarely found in normal adult cells.
«People have been
targeting telomerase as a potential cancer therapy for a long time,» he says, noting that anti-telomerase drugs are in phase II clinical trials against several cancers.
«Obviously, this information can be used in our efforts to identify drug therapies that kill cancer cells by
targeting telomerase activity.»
Through such evolutionary processes, a drug that
targets telomerase could seem effective at first, only to be defeated by the cancer cell line if it can (for instance) more effectively break the drug down, or prevent the drug from entering its cells, or put out the biological equivalents of the «chaff» and flares that are used by fighter jets to ward off the targeting systems of hostile missiles.
Not exact matches
«Our findings have implications for how to think about the earliest processes that drive cancer and
telomerase as a therapeutic
target.
Since then, his team has been creating molecular inhibitors to
target the TRBD RNA - binding pockets as means to inhibit
telomerase enzymatic activity.
Toward the goal of precisely augmenting
telomerase activity selectively within adult stem cells, this discovery reveals the crucial step in
telomerase catalytic cycle as an important new drug
target.
By specifically
targeting the pause signal that prevents restarting DNA repeat synthesis,
telomerase enzymatic function can be supercharged to better stave off telomere length reduction, with the potential to rejuvenate aging human adult stem cells.
In this webinar, our experts will describe the advances in telomere research as it applies to human health and how deeper characterization of the
telomerase maintenance process can uncover
targets for therapies.
Telomerase would be a prime
target for anticancer drugs.
Telomerase is being explored as a
target for therapeutic cancer vaccines.
Generating mouse models to validate telomeres and
telomerase as therapeutic
targets for cancer and age - related diseases.
Telomere lengthening occurs through the activity of
telomerase or the less well understood alternative lengthening of telomeres (ALT) mechanisms: these two are a small set of
targets for modern medicine, and researchers are working on the challenge.
Since the discovery that
telomerase is repressed in most normal human somatic cells but strongly expressed in most human tumors,
telomerase has become a
target for therapeutic agents to combat human cancer.